- Home
- BIRD vs MRSN Comparison
BIRD vs MRSN Comparison
Compare BIRD & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIRD
- MRSN
- Stock Information
- Founded
- BIRD 2015
- MRSN 2001
- Country
- BIRD United States
- MRSN United States
- Employees
- BIRD N/A
- MRSN N/A
- Industry
- BIRD Apparel
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- BIRD Consumer Discretionary
- MRSN Health Care
- Exchange
- BIRD Nasdaq
- MRSN Nasdaq
- Market Cap
- BIRD 50.7M
- MRSN 43.4M
- IPO Year
- BIRD 2021
- MRSN 2017
- Fundamental
- Price
- BIRD $5.15
- MRSN $0.39
- Analyst Decision
- BIRD Buy
- MRSN Buy
- Analyst Count
- BIRD 3
- MRSN 3
- Target Price
- BIRD $12.00
- MRSN $4.00
- AVG Volume (30 Days)
- BIRD 68.5K
- MRSN 3.1M
- Earning Date
- BIRD 05-08-2025
- MRSN 05-08-2025
- Dividend Yield
- BIRD N/A
- MRSN N/A
- EPS Growth
- BIRD N/A
- MRSN N/A
- EPS
- BIRD N/A
- MRSN N/A
- Revenue
- BIRD $189,757,000.00
- MRSN $40,497,000.00
- Revenue This Year
- BIRD N/A
- MRSN N/A
- Revenue Next Year
- BIRD $4.60
- MRSN N/A
- P/E Ratio
- BIRD N/A
- MRSN N/A
- Revenue Growth
- BIRD N/A
- MRSN 9.88
- 52 Week Low
- BIRD $3.93
- MRSN $0.26
- 52 Week High
- BIRD $18.34
- MRSN $3.63
- Technical
- Relative Strength Index (RSI)
- BIRD 48.45
- MRSN 51.49
- Support Level
- BIRD $4.56
- MRSN $0.33
- Resistance Level
- BIRD $5.05
- MRSN $0.38
- Average True Range (ATR)
- BIRD 0.59
- MRSN 0.05
- MACD
- BIRD 0.03
- MRSN 0.02
- Stochastic Oscillator
- BIRD 51.17
- MRSN 76.70
About BIRD Allbirds Inc.
Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.